AstraZeneca in two more Seroquel XR patent settlements; Actavis outlines South America aims

6 October 2011

In further patent settlements in the USA, Anglo-Swedish drug major AstraZeneca (LSE: AZN) has now announced agreements with two more companies - Accord Healthcare and its Indian parent company Intas Pharmaceuticals - relating to Accord’s proposed generic copy of its blockbuster antipsychotic drug Seroquel XR (quetiapine, extended release).

The agreement, or pay-for-delay deal, settles the patent infringement litigation filed by AstraZeneca following Accord's submission to the US Food and Drug Administration of an Abbreviated New Drug Application for a generic Seroquel XR. Under the deal, Accord does not dispute that the patent asserted by AstraZeneca in the US patent litigation is valid and enforceable.

As part of the agreement, AstraZeneca has granted Accord a licence to enter the US market with generic Seroquel XR on November 1, 2016, or earlier upon certain circumstances. Seroquel XR is protected by patents and other exclusivity rights that range from March 2012 to November 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK